FDA: Page 49


  • FDA mulls new incentives to stem antimicrobial resistance

    The agency is working to smooth approval pathways for new products, while proposing changes to reimbursement to account for limited use.

    By Suzanne Elvidge • June 13, 2018
  • Image attribution tooltip
    Adobe Stock
    Image attribution tooltip

    CMS sets goals to tackle opioid crisis

    The plan calls for greater data transparency, as well as use of a Medicare heat map to pinpoint areas that can benefit from targeted safe prescribing efforts.

    By Meg Bryant • June 12, 2018
  • Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    AbbVie, Roche win key US approval for blood cancer drug

    Venclexta, when paired with Rituxan, is now cleared for second-line treatment of two related types of leukemia, positioning the drug behind Imbruvica.

    By June 11, 2018
  • EMA moves forward with Amsterdam relocation

    The board of the EU's medicines agency signed off on a plan to keep business moving as the agency moves from London post-Brexit.

    By Suzanne Elvidge • June 11, 2018
  • Image attribution tooltip
    BIO
    Image attribution tooltip

    'Patient-focused' drug development guidance coming, FDA chief says

    Speaking at the BIO International convention, FDA Commissioner Scott Gottlieb also laid out his vision to balance workloads among therapeutic areas.

    By Lisa LaMotta • June 8, 2018
  • BIO18: FDA to issue guidance on cell and gene therapy in July

    Commissioner Scott Gottlieb also said the industry needs to move toward continuous manufacturing of these treatments.

    By Lisa LaMotta • June 7, 2018
  • Image attribution tooltip
    Samsung Bioepis
    Image attribution tooltip

    FDA lays out biosimilar guidance for agency meetings

    One aim of the draft guidance is to speed biosimilars' path to market by improving communication with the regulator. 

    By Suzanne Elvidge • June 6, 2018
  • Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    First Neulasta biosimilar headed to US market

    The FDA has approved Mylan and Biocon's copycat pegfilgrastim, putting even more pressure on the already weakening Amgen franchise.

    By June 6, 2018
  • FDA puts illegal opioid websites on notice, issues warning letters

    Commissioner Scott Gottlieb said the effort is one piece of a broader effort to crack down on opioids sold online and shipped by mail.

    By David Lim • June 6, 2018
  • Image attribution tooltip
    Adobe Stock
    Image attribution tooltip

    AMA trumpets physician efforts in opioid epidemic fight

    The doctors' group said opioid prescriptions are down while prescription drug monitoring program queries are up.

    By Les Masterson • June 1, 2018
  • Lilly's baricitinib gets FDA OK, but faces hurdles

    The big pharma finally garnered approval for its rheumatoid arthritis drug, but only got clearance for the lower dose. 

    By Lisa LaMotta • June 1, 2018
  • FDA working to mitigate critical drug shortages

    Drug shortages can impede access to important drugs — something the agency aims to prevent in the future.

    By Suzanne Elvidge • June 1, 2018
  • Column

    Prescribed Reading: M&A slow ahead of BIO, ASCO

    With two of the industry's biggest conferences coming up, the biopharma deal space took a breath. 

    By Lisa LaMotta • June 1, 2018
  • Vertex, CRISPR gene-editing therapy hit with clinical hold

    Though CTX001 now faces a delay in the U.S., CRISPR and Vertex still plan to initiate a Phase 1/2 study of it in Europe later this year.

    By May 31, 2018
  • FDA launches medical device 'innovation challenge' to combat opioid crisis

    The agency is dangling its Breakthrough Device designation to spur products, including diagnostics to identify those at high risk of addiction and pain.

    By David Lim • May 31, 2018
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    TherapeuticsMD garners FDA OK for Imvexxy

    After a prior rejection, the women's health company gets the go-ahead for its estrogen capsule for pain during sex.

    By Lisa LaMotta • May 30, 2018
  • EU refines IP rules to boost biosimilars and generics

    The European Commission is loosening an IP law to improve the competitiveness of EU drugmakers in the global generic and biosimilar market.

    By Suzanne Elvidge • May 29, 2018
  • BioMarin cleared to bring new PKU drug to market

    A wholesale acquisition cost of $192,000 puts Palynziq at a premium compared to BioMarin's other marketed PKU drug Kuvan.

    By May 25, 2018
  • Column

    Prescribed Reading: J&J seen with most M&A potential; Drug pricing plan ripples

    The pharma giant has the greatest flexibility to ink a deal, according to a recent Leerink report. Elsewhere, drug pricing remained center stage in D.C. 

    By Lisa LaMotta • May 25, 2018
  • Recro plummets on CRL

    Stock in the Pennsylvania biotech swung from a 52-week high to a low after the FDA rejected its intravenous, non-opioid pain drug.

    By May 24, 2018
  • FDA issues draft guidance on topical drug ingredients

    The agency is taking a closer look at how API are absorbed through the skin now that better technologies allow for more accurate monitoring. 

    By Suzanne Elvidge • May 24, 2018
  • Right to Try bill clears House, headed for Trump signature

    FDA chief Scott Gottlieb had expressed reservations about the impact on agency authority.

    By David Lim • May 22, 2018
  • Early 340B hospitals gave more uncompensated care than later participants

    The research comes as Congress and President Donald Trump have called into question whether the program has outgrown its intent.

    By David Lim • May 22, 2018
  • FDA approves first TPO agonist for chronic liver disease

    Dova's Doptelet, available in June, will be the first oral option for liver disease patients with thrombocytopenia.

    By Suzanne Elvidge • May 22, 2018
  • Senate Dem says raising drug prices abroad won't help US

    The generic drug lobby has concerns that tariffs proposed by the Trump administration, including on pharmaceutical ingredients and products from China, would lead to increased manufacturing costs and higher drug prices.

    By David Lim • May 21, 2018